Background
==========

Coronary artery disease is a health care issue of epidemic proportions, and has a profound impact on resource utilization. A quiescent atherosclerotic lesion may follow the course of progressive luminal encroachment, or succumb to an acute thrombotic event. Reduced *de novo* collagen synthesis and increased extracellular matrix metabolism contribute to weakening of the fibrous cap \[[@B1]\]. Platelet aggregation is a crucial component of this process. Coronary artery bypass grafting (CABG) remains the best management option for patients with severe multi-vessel coronary artery disease \[[@B2]\][\]]{.smallcaps}. It has been subjected to an unparalleled level of scientific scrutiny. The continuous trend toward improving patient outcomes following CABG stems from refinement of the technical aspects of the procedure, as well as optimization of the adjuvant pharmacologic therapy.

Antiplatelet management following CABG
--------------------------------------

Platelet inhibition is paramount in the management of coronary artery disease. Antiplatelet drugs reduce mortality and the incidence of major vascular events in patients with a wide variety of vascular occlusive pathologies \[[@B3]\]. Their beneficial effects must be, however, balanced against the associated risk of bleeding. Acetylsalicylic acid (ASA) is currently recommended after CABG in order to improve long-term graft patency \[[@B4]\][\]]{.smallcaps}. The recommended doses range from 150 to 325 mg, with a trend towards clinical benefit when higher doses are utilized within the first year \[[@B4]\][\]]{.smallcaps}. There is no compelling evidence to support the superiority of clopidogrel to ASA monotherapy in optimizing graft patency following CABG \[[@B4]\][\]]{.smallcaps}. The mechanisms of action of thienopyridines and ASA differ, allowing for a cumulative anti-aggregative effect \[[@B3],[@B5]\]. ASA irreversibly suppresses cyclooxygenase-1 activity thereby reducing thromboxane A2 production, whereas clopidogrel acts on the P2Y12 adenosine diphosphate (ADP) receptor to inhibit ADP-mediated platelet aggregation \[[@B6],[@B7]\]. While dual antiplatelet therapy offers a reduction in atherosclerotic events in patients undergoing percutaneous coronary interventions, this benefit has not been reliably reproduced in other clinical settings \[[@B7],[@B8]\][\].]{.smallcaps}

[I]{.smallcaps}ndividual variability to antiplatelet agents
-----------------------------------------------------------

The incidence of interpatient variability to antiplatelet drugs depends upon the laboratory evaluation used to diagnose it \[[@B7]\]. Novel tools for quantifying drug induced platelet inhibition have brought into focus the individual variations in antiplatelet responses. This underscores the importance of identifying the optimal antiplatelet drug protocol in order to achieve the targeted level of anti-aggregation. Multiple electrode aggregometry (MEA) has been shown to be a useful instrument in the quantification of platelet inhibition by ASA \[[@B6]\]. Its mechanism of assessing platelet inhibition is based on changes in impedance on its sensor wires secondary to platelet adherence. Aspirin resistance has been suggested to range anywhere from 1 to 45% \[[@B7]\]. The efficacy of ASA absorption, TXA2 independent platelet activation pathways, COX-1 gene mutations, as well as ASA interactions with other medications have all been postulated to play a role in inducing aspirin resistance \[[@B9]\]. The response to ASA should best be viewed as a continuous variable. Dichotomizing patients into responders or non-responders is, however, suitable for scientific research and is commonly employed for this purpose \[[@B7]\]. The presence of ASA low-responsiveness has been linked to an increase in cardiovascular morbidity \[[@B9]\]. The clinical correlation of individual patient refractoriness to ASA with an increased incidence of cardiovascular complications is fundamental to the present study. This will be, to the best of our knowledge, the first prospective randomized study that will aim to evaluate whether the combination of ASA and clopidogrel in ASA-resistant CABG patients offers a clinical benefit. Our hypothesis that a dual antiplatelet regime will improve patient outcomes in this setting stems from the convergence of the clinical impact of ASA resistance and the benefit gained from adding clopidogrel to ASA in certain clinical scenarios.

Methods
=======

Study population
----------------

All consecutive patients aged 18 years or more, scheduled for an elective surgical myocardial revascularization procedure using cardiopulmonary bypass over the study period, at the University Hospital Center Zagreb, will be screened for the study. Written informed consent will be obtained from all patients prior to enrolment into the study. The preoperative exclusion criteria will include valvular pathology warranting surgical correction, critical preoperative state, inability to provide informed consent, reoperation, any medical condition for which dual antiplatelet therapy is indicated, redo-CABG, off-pump CABG, preoperative antiplatelet therapy other than ASA or clopidogrel, preoperative anticoagulation with coumadin and history of cerebrovascular accidents. Furthermore, patients who require postoperative anticoagulation, intra-aortic balloon pump support, or who die prior to postoperative day 4 will not be included into the study. All other consecutive isolated CABG patients will be screened for the study. Those patients who exhibit aspirin resistance on their MEA evaluation on postoperative day 4 will then be randomized into two groups.

Ethics
------

The Ethics Committee of the University Hospital Center Zagreb has evaluated and approved the conduct of this study (No. 01/001/VG) on 23 June 2010. Ethical standards in line with the Declaration of Helsinki involving research on human subjects will be strictly adhered to. This protocol complies with the CONSORT guidelines \[[@B10]\].

Sample size
-----------

An exact binomial test power analysis was performed in order to estimate the approximate sample size required to test the null hypothesis. The minimum effect size was 10%. Accounting for a maximum estimated 10% loss to follow-up, a total of 219 patients will be required to test the null hypothesis with an α value of 0.05 and a power of 0.8.

Aspirin low-responsiveness
--------------------------

The ASPI test evaluates cyclooxygenase-dependent platelet aggregation (using arachidonic acid) that is sensitive to aspirin. Our definition of low response to ASA will be based upon our own published experience with multiple electrode aggregometry in a similar population of patients \[[@B11]\]. In brief, patients in the aforementioned study were divided into quartiles with respect to their ASA responsiveness, and those in whom the ASPI test was greater than the 75^th^ percentile of the entire cohort (that is, area under the curve, AUC ≥ 30 units) were defined as being ASA low-responders \[[@B11]\]. This definition has been corroborated by published data from other sources \[[@B12]-[@B14]\].

Randomization of patients and interventional strategy
-----------------------------------------------------

All post-CABG patients in whom none of the postoperative exclusion criteria have occurred will undergo MEA analysis on postoperative day 4. Patients found to have evidence of ASA low-responsiveness, as defined by an ASPI test ≥ 30 AUC, will undergo randomization into either the control group or the dual antiplatelet therapy (dAPT) group. Assignment to either group will be performed by random allocation using randomization software \[[@B15]\]. Patients in the control group will continue to receive 300 mg of ASA in accordance to our hospital's standard post-CABG antiplatelet management strategy. Patients in the dAPT group will, conversely, be subjected to augmentation of their antiplatelet regime by receiving 75 mg of clopidogrel in addition to the 300 mg of ASA. A flowchart depicting the screening and randomization protocols is shown in Figure [1](#F1){ref-type="fig"}.

![**Flowchart detailing the screening algorithm for patient recruitment, followed by subsequent randomization into the aspirin monotherapy or dual antiplatelet therapy groups.** CABG, coronary artery bypass grafting; MEA, multiple electrode aggregometry; ASPI, cyclooxygenase dependent platelet aggregation, AUC, area under the curve; ASA, acetylsalicylic acid; MACCE, major adverse cardiac and cerebrovascular events.](1745-6215-13-148-1){#F1}

Preoperative antiplatelet therapy management
--------------------------------------------

Preoperative antiplatelet therapy is managed by the referring cardiologist. It almost uniformly consists of 100 mg of ASA and this is continued up to the day of surgery. Some patients receive clopidogrel in addition to ASA in the preoperative period. Clopidogrel will be discontinued 5 days prior to the scheduled revascularization procedure. All patients included in the study will have received antiplatelet therapy for no less than 14 days prior to enrolment.

Perioperative management
------------------------

The perioperative management of study patients will not deviate from our hospital's standard preoperative anesthetic regime, which includes diazepam and morphine prior to induction of anesthesia. Endotracheal tube, urinary catheter, radial artery and pulmonary artery catheters will be inserted. Our protocol will consist of induction and maintenance of anesthesia with midazolam, fentanyl and pancuronium bromide. This will be complemented with sevoflurane inhalation. The initial ventilator settings will consist of a tidal volume of 8 ml/kg, and a respiratory rate of 12 breaths per minute. Systemic heparinization with a target-activated clotting time \> 480 seconds will be utilized, followed by full reversal with protamine after decannulation. The cardiopulmonary circuit will include the Medtronic Affinity Trillium membrane oxygenator, venous reservoir and PVC tubing (Medtronic, Minneapolis, USA) and a Stoeckert III roller pump (Stoeckert, Munich, Germany). The ascending aorta and right atrium will be cannulated for cardiopulmonary bypass (CPB). The CPB flow will approximate 2.4 L/min/m^2^. Every effort will be made to maintain the mean systemic pressure during CPB between 60 and 80 mmHg. Vasopressors will be used as needed in order to achieve the target mean pressure. The patient's temperature will be allowed to drift down to 32 to 34°C. Myocardial protection will be based upon a combination of antegrade and retrograde cardioplegia, coupled with topical cooling. Both the coronary and the proximal aortic anastomoses will be performed on an arrested heart, during a single period of aortic cross-clamping. Weaning from CPB will typically be performed without inotropic support. In patients in whom the cardiac index will remain below 2.2 L/min/m^2^, dobutamine will be administered. Norepinephrine will be instituted if dobutamine produces excessive vasodilatation. Escalation of vasoactive support, if necessary, will include the addition of another inotrope, an intra-aortic balloon pump or mechanical circulatory assistance.

Postoperative medications will typically include a beta blocker, a hydroxy-methyl-glutaryl-CoA reductase inhibitor and a diuretic. Electrolytes will be supplemented as indicated. An ACE inhibitor will be instituted, as tolerated. Peptic ulcer prophylaxis will be universally implemented, and continued for six weeks postoperatively. Non-steroidal anti-inflammatory drugs will generally not be administered in the early postoperative period. The antiplatelet regime will be based upon the previously mentioned randomization protocol.

Blood sampling
--------------

Blood samples for MEA measurements will be obtained on postoperative day (POD) 4 via peripheral venipuncture. The search for an ideal anticoagulant for blood samples used for the quantification of platelet function is still ongoing. Heparin will be the anticoagulant used in the present study \[[@B16],[@B17]\]. Blood will be collected in 4 ml heparin (Lithium Heparin 68 IU)-coated BD Vacutainer plastic tubes. Routine laboratory evaluations will be performed and recorded preoperatively and on POD 4. The same person, who has no direct involvement in either patient care or postoperative follow-up, will perform all MEA measurements. Blood samples will be allowed to rest for 30 minutes after blood withdrawal and MEA will be performed subsequently.

Multiple electrode aggregometry (MEA)
-------------------------------------

Whole blood aggregability will be determined using a new generation impedance aggregometer (Multiplate® analyzer, Dynabyte Medical, Munich, Germany). The method has been described in detail previously, and has already been validated \[[@B18]\]. In brief, the principle underlying MEA is that platelets are non-thrombogenic in their resting state, but have the potential to present multiple surface receptors when activated, which enables them to attach to a variety of surfaces. The accumulation of platelets on the Multiplate sensor wires will increase the electrical resistance between them. This variability in impedance, which is expressed in arbitrary AUC units, is the MEA parameter with the highest diagnostic value \[[@B18],[@B19]\]. The analysis takes 3 minutes for incubation and 6 minutes for the post-stimulation measurement. Platelet aggregation was determined in response to stimulation with arachidonic acid with a final concentration of 0.5 mM (ASPI test designed to evaluate ASA effect) and ADP with a final concentration of 6.4 μM (ADP test designed to evaluate thienopyridines, that is, clopidogrel).

Patient follow-up
-----------------

Prospective collection of the follow-up data will be carried out postoperatively via three bimonthly telephone interviews over the initial 6 months. Three surgical residents will perform the acquisition of the follow-up data. The telephone interview will be based upon a customized questionnaire, which incorporates information critical to the present study. Follow-up data will then be stored in a central database. Patients in whom the interview revealed equivocal information pertinent to the study will be asked to consign their medical records for further review by a cardiac surgeon and a cardiologist blinded to the study protocol. In the case that the opinions of the two reviewers differ, a third reviewer will offer an opinion, which will then be considered definitive and will be stored in the central database.

Outcome definitions
-------------------

The primary clinical endpoint of the study will be the incidence of major adverse cardiac and cerebrovascular events (MACCE) in relation to two distinct antiplatelet strategies (ASA monotherapy or dual antiplatelet therapy) in patients found to be ASA-resistant. MACCE will be defined as a composite endpoint consisting of all-cause mortality, non-fatal myocardial infarction, cerebrovascular accident and cardiovascular rehospitalization. The definition of perioperative and postoperative myocardial infarction will be based upon published recommendations of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the Redefinition of Myocardial Infarction \[[@B20]\]. The definition of stroke will be based upon a new onset focal neurological deficit lasting \> 24 hours or an imaging study suggestive of an acute clinically relevant cerebral lesion in patients with rapid recovery \[[@B21]\].

Bleeding events will constitute the secondary clinical endpoint. They will be stratified in accordance to the consensus report from the Bleeding Academic Research Consortium (BARC). In brief, the hemorrhagic complications according to the BARC scale range from type 1, which denotes bleeding that is not actionable, to type 5 which is defined as a bleeding-related fatal event \[[@B22]\]. Type 0 denotes the absence of bleeding \[[@B22]\].

Statistical analysis
--------------------

The continuous data will be presented as mean values ± standard deviation (SD) or medians with their respective interquartile range. Categorical variables will be presented as absolute numbers with percentages. Analyses of continuous data between different groups of patients will be performed using the Mann-Whitney *U*-test. Differences between categorical variables will be evaluated with Fisher's exact test. A two-tailed *P*-value will be used amd *P* \< 0.05 will be considered significant for all deployed statistical calculations. The data will be processed using the Statistica 9 software package (StatSoft Inc., Tulsa, USA).

Discussion
==========

The disruption of the integrity of atherosclerotic lesions followed by secondary thrombosis is recognized as the primary lesion responsible for a variety of acute ischemic syndromes \[[@B9]\]. Continued improvement of surgical outcomes in patients with coronary artery disease is the result of a convergence of technical progress and better tailoring of pharmacotherapy. The fundamental goal of this study is to test the hypothesis that tailored modulation of platelet activity based on reproducible laboratory measurements of antiplatelet drug responses has the potential for improving patient outcomes following CABG. Patients with documented aspirin resistance early after CABG will be randomized to receive either additional clopidogrel or no augmentation of their anti-aggregation management. The incidence of MACCE will be recorded, as well as the safety profile in terms of bleeding events for both treatment arms.

The design of this study is a prospective randomized one. It will enrol consecutive cardiac surgical patients based upon pre-specified criteria. The discriminatory variable among the screened patients will be a reproducibly quantifiable deficiency in their antiplatelet therapy response. This will create a homogenous patient population, allowing for a robust analysis. We believe that the adverse impact of aspirin resistance on patient outcomes coupled with its relative frequency add merit to a study such as this. It is paramount, however, to objectively weigh the hypothetical benefit of dual antiplatelet therapy against the potentially increased susceptibility for bleeding. The benefit of dual antiplatelet therapy has not been universally reproducible in all publications dealing with the subject. Kulik *et al*. have evaluated the effect of adding clopidogrel to ASA on the degree of intimal hyperplasia in saphenous vein coronary artery bypass grafts \[[@B23]\]. No significant reduction in intimal hyperplasia was observed in that study \[[@B23]\]. Conversely, Gao and coauthors documented superior venous graft patency with dual antiplatelet therapy in comparison to ASA monotherapy \[[@B24]\]. Neither of these studies explored the impact of interpatient variability to antiplatelet drug therapy on patient outcomes. The strategy of adding a thienopyridine to patients who have been found to be ASA resistant following CABG has thus far been unexplored. The present trial is designed to offer more information on that specific subject.

Should the results of this study prove to document superiority of the dual antiplatelet regime in patients found to be aspirin resistant, this could promote an alteration of the contemporary management of platelet inhibition in patients undergoing CABG towards a more aggressive approach.

Trial status
============

Patient recruitment for the study is currently ongoing.
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